News from cstone pharmaceuticals A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 30, 2019, 06:23 ET ESMO 2019: CStone presents pooled safety data from the Phase 1b trial of CS1001, demonstrating promising overall safety and tolerability

CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) released pooled safety data from the Phase Ib (GEMSTONE-101) study of the Company's...


Sep 21, 2019, 21:25 ET 2019 CSCO| CStone announces promising ORR, anti-tumor activity and safety data with its anti-PD-L1 antibody CS1001 in MSI-H/dMMR solid tumors

CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced results from the microsatellite instability high/deficient mismatch...


Sep 21, 2019, 21:23 ET 2019 CSCO | CStone announces preliminary results from Phase I trial of CS1002 demonstrating characteristics comparable to ipilimumab

CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced preliminary results from the Phase Ia trial of the Company's...


Sep 20, 2019, 12:22 ET 2019 CSCO | CStone releases preliminary results from the Phase Ia trial of CS1003 in Chinese patients with advanced tumors

CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today released the preliminary data from the Phase I bridging study of the Company's...


Sep 19, 2019, 11:36 ET 2019 CSCO | CStone announces promising trial data on its anti-PD-L1 antibody in esophageal squamous cell carcinoma with an ORR of 77.8%

CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced trial data from the esophageal squamous cell carcinoma (ESCC) cohort...


Aug 25, 2019, 23:25 ET CStone announces first patient dosed in China for Phase I/II registrational bridging trial of avapritinib in advanced GIST

CStone Pharmaceuticals ("CStone", HKEX: 2616) today announced that the first patient in China has been dosed in the Phase I/II bridging study of...


Aug 22, 2019, 23:24 ET CStone announces data from trials of CS1001, CS1002 and CS1003 to be released for the first time at 2019 CSCO Annual Meeting

CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the 22nd Annual Meeting of the Chinese Society of Clinical...


Aug 22, 2019, 23:21 ET CStone completes registration filing for the Phase I trial of CDK4/6 inhibitor CS3002 in Australia and will soon initiate the study

CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the Company has recently received ethics approval from the Human...


Aug 19, 2019, 22:18 ET CStone submits an abstract on CS1001-201 trial to 2019 ASH Annual Meeting

CStone Pharmaceuticals ("CStone", HKEX: 2616) today announced that an abstract on the company's CS1001-201 trial has been submitted to the upcoming...


Aug 19, 2019, 01:50 ET Abstract on CStone's CS1001-101 trial accepted for poster presentation at ESMO 2019 Annual Congress

CStone Pharmaceuticals ("CStone", HKEX: 2616) today announced that an abstract on the company's ongoing CS1001-101 Phase Ib clinical study has been...


Aug 15, 2019, 03:31 ET CStone Pharmaceuticals Reports First Half 2019 Financial Results

CStone Pharmaceuticals ("CStone"; HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative...


Aug 13, 2019, 00:21 ET CStone announces first patient dosed in China with BLU-667 for the global Phase I registrational study

CStone Pharmaceuticals ("CStone", HKEX: 2616) today announces the dosing of the first patient in China for the Phase I registrational study of...


Aug 07, 2019, 02:47 ET CStone to Build Global R&D Headquarters and Industrialization Base in the Suzhou Industrial Park

The signing ceremony for CStone Pharmaceuticals' ("CStone") (HKEX: 2616) Global R&D Headquarters and Industrialization Base ("the Project") took...


Jul 22, 2019, 00:17 ET CStone receives approval in China to initiate ivosidenib Phase I bridging registrational study for the treatment of IDH1 mutant relapsed or refractory AML

CStone Pharmaceuticals ("CStone"; HKEX: 2616) announced today that it has received approval from China National Medical Products Administration...


Jul 09, 2019, 22:23 ET CStone announces first patient dosed in China with avapritinib in global Phase III clinical trial in advanced GIST

CStone Pharmaceuticals ("CStone", HKEX: 2616) today announced that the first patient has been dosed in China with avapritinib in the ongoing global...


Jun 09, 2019, 21:30 ET CStone and Bayer announce global collaboration to evaluate PD-L1 monoclonal antibody CS1001 in combination with regorafenib

CStone Pharmaceuticals ("CStone"; HKEX: 2616) today announced that the company has entered into a global clinical collaboration with China focus with ...


Jun 05, 2019, 07:56 ET CStone received approval to initiate clinical development in China of CS1001 and BLU-554 (CS3008) in combination therapy for HCC

CStone Pharmaceuticals (CStone; HKEX: 2616) announced that it has received approval to initiate clinical development in China of CS1001 in...


Jun 02, 2019, 23:45 ET CStone submits new drug application for TIBSOVO(R) in Taiwan for the treatment of relapsed/refractory AML

CStone Pharmaceuticals ("CStone", HKEX: 2616) announced that a new drug application (NDA) for TIBSOVO® (ivosidenib) has been submitted by a...


May 23, 2019, 06:01 ET Cstone partner Agios Announces the Phase 3 ClarIDHy Trial of TIBSOVO (ivosidenib) Achieved its Primary Endpoint

The partner of CStone Pharmaceuticals ("Cstone"; HKEX:2616), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) ("Agios") announced that the global Phase 3...


May 01, 2019, 22:59 ET CStone and Numab announce exclusive regional licensing agreement for ND021, a multi-functional drug candidate and potential next-generation immunotherapy

CStone Pharmaceuticals ("CStone"; HKEX: 2616) and Numab Therapeutics AG ("Numab") today announce that they have entered into an exclusive regional...


Apr 16, 2019, 04:50 ET First patient dosed in Phase III GEMSTONE-303 study for CS1001 in combination with chemotherapy in first-line gastric adenocarcinoma and gastro-esophageal junction adenocarcinoma

CStone Pharmaceuticals (the "Company" or "CStone"; HKEX: 2616) announces that the first patient has been successfully enrolled and dosed in a Phase...


Apr 15, 2019, 02:32 ET CStone received IND approval in China for avapritinib Phase I/II bridging registrational study in patients with advanced gastrointestinal stromal tumors

CStone Pharmaceuticals ("CStone"; HKEX: 2616) announced today that the National Medical Products Administration (NMPA) recently approved the...


Apr 04, 2019, 11:44 ET CStone Pharmaceuticals presented poster of pre-clinical result for CS1003 at AACR

CStone Pharmaceuticals ("CStone"; HKEX:2616) delivered a poster of pre-clinical data of CS1003 at the 2019 American Association for Cancer Research...


Mar 25, 2019, 03:14 ET CStone appoints three distinguished oncology leaders Drs. Paul A. Bunn, Jr., Elizabeth M. Jaffee and Richard S. Finn to its Scientific Advisory Board

CStone Pharmaceuticals ("CStone"; HKEX: 2616) is pleased to announce the appointment of three internationally renowned oncologists Paul A. Bunn, Jr., ...


Mar 21, 2019, 09:32 ET CStone receives approval in China to initiate Phase 1 clinical trial for RET inhibitor BLU-667 (CS3009)

CStone Pharmaceuticals ("CStone"; HKEX: 2616) today announced that China's National Medical Products Administration (NMPA) has approved the clinical...